A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases.
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2010 Actual patient number (65) added as reported by ClinicalTrials.gov.